Role of Toll-Like Receptor 2 Immune Response in Mycobacterium Tuberculosis and Chronic Obstructive Pulmonary Diseased
DOI:
https://doi.org/10.65336/Keywords:
COPD, Mycobacterium Tuberculosis, TB, TLR-2.Abstract
Background: Mycobacterium Tuberculosis and Chronic Obstructive Pulmonary disease (COPD) are of great public health concern due to high mobility and mortality rate recorded worldwide. Both diseases have similarities in their Immune pathogenesis such as the inflammation increased in the airway and lung parenchyma. Our study aimed at evaluating the implication of TLR2-mediated regulation in the pathogenesis of TB and COPD a pathway poorly elucidated.
Methods: We carried out a retrospective cross sectional study amongst sixty enrolled participants from the Jamot Reference Hospital for Tuberculosis and other pulmonary respiratory diseases in Yaoundé Cameroon. An ethical clearance and consent were obtained from all our enrolled participants. They were confirmed positive cases for either TB using IDR of the tuberculin or COPD forcing expiratory volume in one second/forced vital capacity ratio of less than 70 percent of the predicted value. We collected 4 ml of whole blood into EDTA tubes. The genotyping of TLR-2, was using polymerase chain reaction-restriction fragment length polymorphism while respecting all the standards procedures.
Results: Of the total of 60 participants enrolled. In total (33%) were TB positive, (33%) COPD positive and 20 healthy controls. Both TB and COPD infection participants had their TLR-2 receptor higher than the control group 0.20ng/dl-0.80ng/dl whereas the level of the control was lower than 0.20g/dl it ranges from with a (P < 0.001).
Conclusions: From our study we could suggest that the Toll-like receptor 2 polymorphism response is imperatively important in studying the immunopathology of this disease and could open different horizons in research in this domain.
References
1. World Health Organization. (2023). Global tuberculosis report 2023. WHO Press.
2. Global Initiative for Chronic Obstructive Lung Disease. (2024). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2024 report.
3. Byrne, A. L., et al. (2015). Tuberculosis and chronic respiratory disease: A systematic review. International Journal of Infectious Diseases, 32, 138–146.
4. Thoma-Uszynski, S., et al. (2001). Induction of direct antimicrobial activity through mammalian Toll-like receptors. Science, 291, 1544–1547.
5. Underhill, D. M., et al. (1999). TLR2 is recruited to macrophage phagosomes. Journal of Experimental Medicine, 189, 1616–1626.
6. Barnes, P. J. (2016). Inflammatory mechanisms in chronic obstructive pulmonary disease. Journal of Allergy and Clinical Immunology, 138, 16–27.
7. Ogus, A. C., et al. (2004). TLR2 Arg753Gln polymorphism is a risk factor for tuberculosis. European Respiratory Journal, 23, 219–223.
8. Ben-Ali, M., et al. (2004). TLR2 Arg677Trp polymorphism and tuberculosis in Tunisia. Clinical Infectious Diseases, 39, e79–e82.
9. Drennan, M. B., et al. (2004). TLR2-deficient mice succumb to Mycobacterium tuberculosis infection. American Journal of Pathology, 164, 947–954.
10. Reiling, N., et al. (2002). TLR2 and TLR4 are not required for Mycobacterium tuberculosis control. Journal of Immunology, 168, 4018–4023.
11. Kleinnijenhuis, J., et al. (2011). Innate immune recognition of Mycobacterium tuberculosis. Clinical and Developmental Immunology, 2011, Article 405310.
12. Haw, T. J., et al. (2018). TLR2 and TLR4 expression in chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology, 58, 99–108.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
